Final Contrast Imaging Guidance Addresses Some, Not All, Industry Critiques
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's guidance on the intersecting regulatory pathways of imaging devices and contrast agents clarifies what marketing submissions are needed for various types of product changes, but still does not address data requirements for specific indications, such as breast cancer imaging.